Retrospective Study Of Laboratory Indicators And Anti-rheumatic Drugs In Patients With RA And SLE

Objective:Analyze the correlation between the different dosing schemes of patients with rheumatoid arthritis(RA)and systemic lupus erythematosus(SLE)in a hospital’s hematology,immunology disciplines and the test indicators tested before treatment,and infer whether the test indicators tested before treatment It is helpful to formulate individualized drug administration plan,analyze the rationality of medication and pharmacologically monitor patients,reduce the incidence of adverse reactions of patients,and ensure the safety,rationality and effectiveness of medication.Methods:A total of 51 5 patients with RA and 211 with SLE were selected from January 2015 to November 2019 in the Department of Hematology and Immunology.Record the general condition of all patients(such as age and gender),laboratory test indicators(such as white blood cell count,rheumatoid factor,erythrocyte sedimentation rate,C-reactive protein,complement C3,complement C4,IgG,IgA,IgM)and other data before treatment.The patients were divided into different dosing regimen groups according to their medication.Rheumatoid arthritis is divided into the following four groups:Group Ⅰ is only used to improve the condition of anti-rheumatic drugs(DMARDs),GroupⅡ is DMARDs+Cloud G,Group Ⅲ is DMARDs+glucocorticoid,Group Ⅳ is DMARDs+Cloud G+glucocorticoid;SLE is divided into the following four groups:Group Ⅰ is uses only to glucocorticoid(GC),Group Ⅱ is GC+hydroxychloroquine,Group Ⅲ is GC+immunosuppressant,Group Ⅳ is GC+hydroxychloroquine+immunosuppressant.SPSS 24.0 and Prism 8.0.1 statistical software were used for statistical analysis,P<0.05 indicated statistical significance.Results:1.The comparison analysis results of various test indexes of different dosing regimens of RA patients show that the average value of Group Ⅱ in WBC is 6.70 ± 2.27,which is significantly lower than the other three groups;the median value of Group II in RF is 67.70(11.80,199.00),Significantly lower than Groups Ⅲ and Ⅳ;CRP Group Ⅱ had a median value of 8.70(3.17,27.50)and Group Ⅳ with a median value of 8.63(3.17,41.38),both groups were significantly lower than Group Ⅰ and Group Ⅲ;The median value of Group Ⅱ in ESR was 30.85(16.08,54.03),and the median value of Group Ⅳ was 34.70(17.20,55.60).The values of both groups were significantly lower than those of Group Ⅰ and Group Ⅲ.There was no statistical significance between the two groups of GC laboratory indexes(P>0.05).Cloud G use group WBC average is 7.18±57,RF average is 265.81±561.42,CRP average is 24.97± 36.18,ESR average is 37.20 ± 25.69,non-use group WBC average is 8.43 ± 3.62,RF average It is 446.21 ±813.26,the average CRP is 54.58 ± 60.54,and the average ESR is 57.01 ± 30.39.Comparing the test indexes of the two groups,the average WBC,RF,ESR,CRP of the non-use group is significantly higher than that of the use group,P<0.05 Statistical significance.2.The comparison analysis results of various test indexes of different dosing regimens of systemic lupus erythematosus patients showed that the average value of WBC Group Ⅱ was 6.07± 3.50,which was significantly lower than that of Group Ⅲ and Group Ⅳ.The comparative analysis results of various test indexes of different medications of hydroxychloroquine and immunosuppressants showed that P>0.05,which was not statistically significant.Conclusion:1.The four laboratory indicators of WBC,RF,CRP,and ESR are helpful for the development of individualized drug administration programs for patients with rheumatoid arthritis.Patients with high WBC and ESR values are recommended to use Group Ⅰ(DMARDs only),patients with high RF and CRP values are recommended to use Group Ⅲ(DMARs+GC),and patients with low WBC,RF and ESR values are recommended Use Group Ⅱ(DMARDs＋Cloud G)dosing regimen,patients with low CRP values are recommended to use Group Ⅳ(DMARDs+Cloud G+GC)dosing regimen.Cloud G is not recommended for patients with high WBC,RF,CRP,and ESR values,and glucocorticoids have no correlation with laboratory indicators.2.WBC helps formulate individualized dosing regimens for patients with systemic lupus erythematosus.Patients with low WBC values are recommended to use Group Ⅱ(GC+hydroxychloroquine)dosing regimen,and patients with high WBCs are recommended to use Group Ⅲ(GC+immunosuppressant)dosing regimen.Hydroxychloroquine and immunosuppression have no correlation with laboratory indicators.